Modified monocytes / macrophages expressing chimeric antigen receptors and uses thereof

JP7600081B2Active Publication Date: 2024-12-16THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021187803
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-07-28
Filing Date
2021-11-18
Publication Date
2024-12-16
Estimated Expiration
2036-07-28

AI Technical Summary

Technical Problem

Existing cancer treatments using chimeric antigen receptors (CARs) on T cells are limited in efficacy for solid tumors due to impaired infiltration, poor trafficking, and an immunosuppressive tumor microenvironment, leading to reduced effectiveness in targeting tumor cells.

Method used

Engineering monocytes, macrophages, or dendritic cells with chimeric antigen receptors (CARs) that include an antigen binding domain, transmembrane domain, and intracellular domain of stimulatory and/or costimulatory molecules to enhance targeted effector activities such as phagocytosis, cellular cytotoxicity, and antigen presentation.

Benefits of technology

The engineered cells effectively infiltrate and target tumor cells, enhancing immune response and tumor cell killing, overcoming limitations of CAR-T cell treatments in solid tumors by improving specificity and invasiveness.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007600081000001
    Figure 0007600081000001
  • Figure 0007600081000002
    Figure 0007600081000002
  • Figure 0007600081000003
    Figure 0007600081000003
Patent Text Reader

Abstract

Methods and compositions for treating cancer, whether solid tumors or hematologic malignancies, are provided. [Solution] Provided are modified cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain, a transmembrane domain, and the intracellular domain of a stimulatory molecule and / or a costimulatory molecule, and the cells are monocytes, macrophages, or dendritic cells possessing targeted effector activity; pharmaceutical compositions comprising the modified cells and a pharmaceutically acceptable carrier; and methods for treating diseases or conditions associated with immunosuppression, such as cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Improved adenoviral vectors and methods of use thereof

    JP2009523007A

  • Methods for treating solid tumors

    JP2013525305A

  • Chimeric antigen receptor

    WO2013051718A1